Elsevier

Life Sciences

Volume 60, Issue 20, 11 April 1997, Pages 1729-1740
Life Sciences

Dextromethorphan protects against cerebral injury following transient, but not permanent, focal ischemia in rats

https://doi.org/10.1016/S0024-3205(97)00132-XGet rights and content

Abstract

Dextromethorphan (DM) has been observed to afford neuroprotection in a variety of in vitro and in vivo experimental models of CNS injury. We have evaluated the neuroprotective activity of DM following both transient (2 h) and permanent focal cerebral ischemia in the rat. Middle cerebral artery occlusion (MCAO) was produced in male Sprague-Dawley rats using the intraluminal filament technique. Animals were dosed s.c with 20 mgkg DM at 0.5, 1, 2, 4, and 6 hours post occlusion. Analysis of brain injury was performed 24 hours after permanent occlusion or reperfusion. Following transient MCAO, vehicle treated rats exhibited a total infarct volume of 203 ± 33 mm3. DM produced a 61% reduction in infarct volume to 79 ± 13 mm3. Permanent MCAO produced a larger infarct volume (406 ± 44 mm3) which was not significantly reduced in size by treatment with DM (313 ± 58 mm3). Infarcted hemispheric oedema was not different in vehicle treated rats following transient or permanent MCAO and was not reduced by DM in either group. Following transient MCAO, rectal temperature was elevated 1,2 and 5 hours post occlusion. While not inducing hypothermia or altering physiological parameters such as blood pressure and blood gases, DM attenuated this injury-related increase in temperature, an effect which appeared to correlate with its ability to protect neurons in temperature regulating hypothalamic centres. The DM-induced reduction in infarction demonstrated in our model of transient focal cerebral ischemia provides further support for the in vivo neuroprotective activity of this compound. Importantly, these data demonstrate the limited neuroprotective efficacy of DM when attempting to combat more severe focal ischemic injuries and imply that drug-induced hypothermia is not ultimately responsible for its protective action.

References (52)

  • D.W Choi

    Brain Res

    (1987)
  • H Monyer et al.

    Brain Res.

    (1988)
  • R.J Radek et al.

    Neurosci Lett.

    (1992)
  • H.J Luhmann et al.

    Neurosci Lett.

    (1994)
  • D.A Prince et al.

    Neurosci Lett.

    (1988)
  • F.C Tortella et al.

    Trends Pharmacol Sci.

    (1989)
  • J Church et al.

    Eur J Pharmacol

    (1985)
  • M.P Goldberg et al.

    Neurosci. Lett.

    (1987)
  • M.A DeCoster et al.

    Brain Res

    (1995)
  • C.L Carpenter et al.

    Brain Res.

    (1988)
  • D.B Jaffe et al.

    Neurosci Lett.

    (1989)
  • K.L Klette et al.

    Brain Res.

    (1995)
  • F.C Tortella et al.

    Brain Res

    (1989)
  • B.Y Wong et al.

    Neurosci Lett

    (1988)
  • D Corbett et al.

    Brain Res.

    (1990)
  • D Xue et al.

    Brain Res.

    (1992)
  • Q Zhao et al.

    Brain Res.

    (1994)
  • H Memezawa et al.

    Brain Res.

    (1995)
  • D.W Choi et al.

    J Pharmacol Exp Ther.

    (1987)
  • F.C Tortella et al.

    Neurosci Lett

    (1995)
  • G.K Steinberg et al.

    Stroke.

    (1988)
  • P.M Bokesch et al.

    Anesthesiology.

    (1994)
  • D Lodge et al.
  • G.L Craviso et al.

    Mol Pharmacol

    (1983)
  • G.L Craviso et al.

    Mol Pharmacol

    (1983)
  • J.M Musacchio et al.

    Mol Pharmacol

    (1989)
  • Cited by (56)

    • Animal models of cerebral ischemia: A review

      2020, Biomedicine and Pharmacotherapy
    • Contrasting roles of immune cells in tissue injury and repair in stroke: The dark and bright side of immunity in the brain

      2017, Neurochemistry International
      Citation Excerpt :

      It will also affect similar regions of the brain, including both the cortex and striatum. However, the lack of reperfusion will consequently limit the chance of hemorrhage and result in central nervous system (CNS) resident microglia playing a more prominent role in stroke pathology (Britton et al., 1997; Kostulas et al., 2002; Li and Stephenson, 2002; Zhang et al., 1995; Burggraf et al., 2005; Lo, 2008a). Recently, methods have been developed that limit the amount of time it takes to induce stroke in mice while simultaneously reducing the variability in infarct location and volume.

    • Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders

      2016, Pharmacology and Therapeutics
      Citation Excerpt :

      In this study, the authors also reported that nifedipine (an L-type VGCC blocker) prevented ERK5 activation to a similar extent as DM, suggesting that DM may in part inhibit VGCCs to regulate ERK5 activity (Wang et al., 2004). Interestingly, in a rat model of transient, focal cerebral ischemia, DM attenuated the injury-related increase in rectal temperature, which was associated with its ability to protect neurons in temperature regulating hypothalamic centers (Britton et al., 1997). A strong correlation between rat rectal and brain temperatures has been shown during focal ischemic insults (Zhang et al., 1993), suggesting that DM may improve outcome in certain ischemic cases by limiting the transient increase in body temperature (Britton et al., 1997).

    • Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord

      2011, Neurobiology of Disease
      Citation Excerpt :

      Lacking the affinity to opioid receptors, DM works as a non-competitive antagonist of NMDA receptors, inhibits voltage gated Ca2+-channels, and stimulates sigma-1 receptors at relatively high doses (Werling et al., 2007). Due to these properties, DM has been shown to be neuroprotective in models of cerebral ischemia, spinal cord injury, epilepsy and Parkinson's disease (Britton et al., 1997; Kim et al., 1996; Steinberg et al., 1988; Topsakal et al., 2002; Zhang et al., 2004). At lower doses, DM or other morphinans are known to inhibit NOX2 mediated production of ROS in activated microglia/macrophages by the reduction of p47phox translocation to the cell membrane through the inhibition of ERK 1/2 phosphorylation (Liu et al., 2009; Qian et al., 2007).

    View all citing articles on Scopus
    View full text